Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Thrombosis in hospitalized patients with viral respiratory infections versus COVID-19

American Heart Journal(2020)10.1016/j.ahj.2020.10.075Source: DataRank Database

Thrombosis in hospitalized patients with viral respiratory infections versus COVID-19 is a research paper published in American Heart Journal (2020). On theSindex it has a DataRank of 0. It has been cited 83 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access83 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)OA: greenTopics (33)Linked Datasets (8)DataCite Reuse (8)IDs (PubMed, PMC)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Varun Subashchandran,Eugene Yuriditsky ORCID,James M. Horowitz ORCID,Harmony R. Reynolds ORCID,Judith S. Hochman ORCID

Live enrichment

PubMed:33181067 PMC:PMC7654304

NHLBI NIH HHS

Grant: R01 HL139909

NHLBI NIH HHS

Grant: R35 HL144993

NHLBI NIH HHS

Grant: K23 HL150315

National Institutes of Health

Grant: 5K23HL150315-04

Mechanisms of Coronary Microvascular Disease

National Institutes of Health

Grant: 5R01HL139909-02

Platelet Activity and Vascular Health in Systemic Lupus Erythematosus

National Institutes of Health

Grant: 5R35HL144993-04

Mechanisms of Platelet Activity in Vascular Disease

National Institutes of Health

greenLicense: Elsevier TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7654304

publisherhttps://api.elsevier.com/content/article/PII:S0002870320303732?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0002870320303732?httpAccept=text/plain

Europe_PMChttps://europepmc.org/articles/PMC7654304

Europe_PMChttps://europepmc.org/articles/PMC7654304?pdf=render

Fields of Study

03 medical and health sciences0302 clinical medicine

MeSH Terms

HumansRespiratory Tract InfectionsPneumonia, ViralMyocardial InfarctionThrombosisHospitalizationRisk AssessmentMiddle AgedUnited StatesFemaleMaleVenous ThromboembolismCOVID-19SARS-CoV-2Ischemic Stroke

Keywords

MaleSARS-CoV-2Pneumonia, ViralMyocardial InfarctionCOVID-19ThrombosisVenous ThromboembolismMiddle AgedRisk AssessmentResearch LettersUnited StatesHospitalizationHumansFemaleRespiratory Tract InfectionsIschemic Stroke

Sustainable Development Goals

SDG 3: 3. Good health

Additional file 1 of Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19

10.6084/m9.figshare.26631046.v1figshare

Additional file 1 of Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19

10.6084/m9.figshare.26631046figshare

Additional file 2 of Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19

10.6084/m9.figshare.26631049.v1figshare

Additional file 2 of Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19

10.6084/m9.figshare.26631049figshare

Additional file 4 of Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19

10.6084/m9.figshare.26631055.v1figshare

Additional file 4 of Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19

10.6084/m9.figshare.26631055figshare

Additional file 3 of Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19

10.6084/m9.figshare.26631052.v1figshare

Additional file 3 of Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19

10.6084/m9.figshare.26631052figshare